{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:48:24Z","timestamp":1769503704849,"version":"3.49.0"},"reference-count":86,"publisher":"Elsevier","isbn-type":[{"value":"9780443192494","type":"print"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.ircmb.2023.05.004","type":"book-chapter","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T08:10:06Z","timestamp":1685434206000},"page":"221-239","source":"Crossref","is-referenced-by-count":4,"title":["Oncolytic virotherapy in lung cancer"],"prefix":"10.1016","member":"78","reference":[{"issue":"19","key":"10.1016\/bs.ircmb.2023.05.004_bib1","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-18-4022","article-title":"Phase I trial of an ICAM-1-targeted immunotherapeutic-Coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer","volume":"25","author":"Annels","year":"2019","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"5","key":"10.1016\/bs.ircmb.2023.05.004_bib2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/1759-7714.13043","article-title":"Updates to the antitumor mechanism of oncolytic virus","volume":"10","author":"Bai","year":"2019","journal-title":"Thoracic Cancer"},{"key":"10.1016\/bs.ircmb.2023.05.004_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/387362","article-title":"Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas","volume":"2013","author":"Boisgerault","year":"2013","journal-title":"BioMed Research International"},{"key":"10.1016\/bs.ircmb.2023.05.004_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/OV.S56322","article-title":"Applications of coxsackievirus A21 in oncology","volume":"3","author":"Bradley","year":"2014","journal-title":"Oncolytic Virotherapy"},{"issue":"8","key":"10.1016\/bs.ircmb.2023.05.004_bib5","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/mt.2010.103","article-title":"Identification of genetically modified Maraba virus as an oncolytic rhabdovirus","volume":"18","author":"Brun","year":"2010","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"1","key":"10.1016\/bs.ircmb.2023.05.004_bib6","first-page":"36","article-title":"Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future","volume":"4","author":"Chan","year":"2015","journal-title":"Translational Lung Cancer Research"},{"issue":"3\u20134","key":"10.1016\/bs.ircmb.2023.05.004_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41417-019-0114-x","article-title":"A chimeric poxvirus with J2R (thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models","volume":"27","author":"Chaurasiya","year":"2020","journal-title":"Cancer Gene Therapy"},{"issue":"22","key":"10.1016\/bs.ircmb.2023.05.004_bib8","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1158\/1078-0432.CCR-10-1233","article-title":"REO-10: A phase I study of intravenous reovirus and docetaxel in patients with advanced cancer","volume":"16","author":"Comins","year":"2010","journal-title":"Clinical Cancer Research: \u0100n Official Journal of the American Association for Cancer Research"},{"issue":"1B","key":"10.1016\/bs.ircmb.2023.05.004_bib9","first-page":"635","article-title":"Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68\/H)","volume":"19","author":"Csatary","year":"1999","journal-title":"Anticancer Research"},{"key":"10.1016\/bs.ircmb.2023.05.004_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2020.10.007","article-title":"Oncolytic herpesvirus therapy for mesothelioma\u2014A phase I\/IIa trial of intrapleural administration of HSV1716","volume":"150","author":"Danson","year":"2020","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"Suppl 3","key":"10.1016\/bs.ircmb.2023.05.004_bib11","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.21037\/tlcr.2019.09.14","article-title":"New generation anaplastic lymphoma kinase inhibitors","volume":"8","author":"Delmonte","year":"2019","journal-title":"Translational Lung Cancer Research"},{"issue":"13","key":"10.1016\/bs.ircmb.2023.05.004_bib12","first-page":"13","article-title":"Measles virus as an oncolytic immunotherapy","author":"Engeland","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/bs.ircmb.2023.05.004_bib13","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.6004\/jnccn.2019.0059","article-title":"NCCN guidelines insights: Non-small cell lung cancer, version 1.2020","volume":"17","author":"Ettinger","year":"2019","journal-title":"Journal of the National Comprehensive Cancer Network: JNCCN"},{"key":"10.1016\/bs.ircmb.2023.05.004_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: An overview","author":"Ferlay","year":"2021","journal-title":"International Journal of Cancer. Journal International du Cancer"},{"issue":"3","key":"10.1016\/bs.ircmb.2023.05.004_bib15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","article-title":"Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer","volume":"70","author":"Galanis","year":"2010","journal-title":"Cancer Research"},{"issue":"11","key":"10.1016\/bs.ircmb.2023.05.004_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113371","article-title":"Promising therapy in lung cancer: Spotlight on aurora kinases","volume":"12","author":"Galetta","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/bs.ircmb.2023.05.004_bib17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1586\/era.10.158","article-title":"Notch signaling in lung cancer","volume":"11","author":"Galluzzo","year":"2011","journal-title":"Expert Review of Anticancer Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.004_bib18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.virol.2015.10.019","article-title":"Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo","volume":"487","author":"Gomez-Gutierrez","year":"2016","journal-title":"Virology"},{"issue":"3","key":"10.1016\/bs.ircmb.2023.05.004_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/07357907.2012.654870","article-title":"Angiogenesis inhibition using an oncolytic herpes simplex virus expressing endostatin in a murine lung cancer model","volume":"30","author":"Goodwin","year":"2012","journal-title":"Cancer Investigation"},{"issue":"6","key":"10.1016\/bs.ircmb.2023.05.004_bib20","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1177\/1078155220931926","article-title":"Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings","volume":"26","author":"Harvey","year":"2020","journal-title":"Journal of Oncology Pharmacy Practice: Official Publication of the International Society of Oncology Pharmacy Practitioners"},{"key":"10.1016\/bs.ircmb.2023.05.004_bib21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/1479-5876-12-197","article-title":"Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice","volume":"12","author":"Hofmann","year":"2014","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.004_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.925985","article-title":"CAR T-cell-based gene therapy for cancers: New perspectives, challenges, and clinical developments","volume":"13","author":"Jogalekar","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/bs.ircmb.2023.05.004_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/156800907780058826","article-title":"Oncolytic virus therapy\u2014Foreword","volume":"7","author":"Kasuya","year":"2007","journal-title":"Current Cancer Drug Targets"},{"issue":"9","key":"10.1016\/bs.ircmb.2023.05.004_bib24","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"6","key":"10.1016\/bs.ircmb.2023.05.004_bib25","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1172\/JCI121323","article-title":"Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival","volume":"129","author":"Kellish","year":"2019","journal-title":"The Journal of Clinical Investigation"},{"issue":"3","key":"10.1016\/bs.ircmb.2023.05.004_bib26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ymthe.2006.05.008","article-title":"Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF","volume":"14","author":"Kim","year":"2006","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"4","key":"10.1016\/bs.ircmb.2023.05.004_bib27","first-page":"13","article-title":"PARP inhibitors in small-cell lung cancer: Rational combinations to improve responses","author":"Knelson","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/bs.ircmb.2023.05.004_bib28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/annonc\/mdx790","article-title":"Radiotherapy and anti-PD-1\/PD-L1 combinations in lung cancer: Building better translational research platforms","volume":"29","author":"Kordbacheh","year":"2018","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO"},{"issue":"10","key":"10.1016\/bs.ircmb.2023.05.004_bib29","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"1","key":"10.1016\/bs.ircmb.2023.05.004_bib30","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1038\/s41467-021-24034-7","article-title":"Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry","volume":"12","author":"Kulkarni","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/bs.ircmb.2023.05.004_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101563","article-title":"Lung cancer and oncolytic virotherapy\u2014Enemy\u2019s enemy","volume":"27","author":"Li","year":"2023","journal-title":"Translational Oncology"},{"issue":"5","key":"10.1016\/bs.ircmb.2023.05.004_bib32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.molmed.2004.03.003","article-title":"Vesicular stomatitis virus: Re-inventing the bullet","volume":"10","author":"Lichty","year":"2004","journal-title":"Trends in Molecular Medicine"},{"issue":"6","key":"10.1016\/bs.ircmb.2023.05.004_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/v13061082","article-title":"Development of group B coxsackievirus as an oncolytic virus: Opportunities and challenges","volume":"13","author":"Liu","year":"2021","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/bs.ircmb.2023.05.004_bib34","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/pcmedi\/pbab027","article-title":"Immunotherapy in non-small cell lung cancer: Rationale, recent advances and future perspectives","volume":"4","author":"Luo","year":"2021","journal-title":"Precis Clin Med"},{"issue":"4","key":"10.1016\/bs.ircmb.2023.05.004_bib35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/0360-3016(92)90660-A","article-title":"Natural alpha-interferon in combination with hyperfractionated radiotherapy in the treatment of non-small cell lung cancer","volume":"23","author":"Maasilta","year":"1992","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"1","key":"10.1016\/bs.ircmb.2023.05.004_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11912-022-01341-w","article-title":"Oncolytic viruses and cancer immunotherapy","volume":"25","author":"Malhotra","year":"2023","journal-title":"Current Oncology Reports"},{"issue":"3","key":"10.1016\/bs.ircmb.2023.05.004_bib37","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1183\/13993003.00359-2016","article-title":"Risk factors for lung cancer worldwide","volume":"48","author":"Malhotra","year":"2016","journal-title":"The European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology"},{"issue":"5","key":"10.1016\/bs.ircmb.2023.05.004_bib38","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1423171","article-title":"Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages","volume":"7","author":"Masemann","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.ircmb.2023.05.004_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107522","article-title":"Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights","volume":"210","author":"Meador","year":"2020","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/bs.ircmb.2023.05.004_bib40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2011.11.008","article-title":"Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo","volume":"317","author":"Meng","year":"2012","journal-title":"Cancer Letters"},{"issue":"12","key":"10.1016\/bs.ircmb.2023.05.004_bib41","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/mt.2009.218","article-title":"Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter","volume":"17","author":"Msaouel","year":"2009","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.004_bib42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.coviro.2020.07.016","article-title":"Measles virus in cancer therapy","volume":"41","author":"Muhlebach","year":"2020","journal-title":"Current Opinion in Virology"},{"issue":"5","key":"10.1016\/bs.ircmb.2023.05.004_bib43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"National Lung Screening Trial Research","year":"2011","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/bs.ircmb.2023.05.004_bib44","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.2000.18.3.609","article-title":"Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer","volume":"18","author":"Nemunaitis","year":"2000","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"5","key":"10.1016\/bs.ircmb.2023.05.004_bib45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.cgt.7700585","article-title":"Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients","volume":"10","author":"Nemunaitis","year":"2003","journal-title":"Cancer Gene Therapy"},{"issue":"21","key":"10.1016\/bs.ircmb.2023.05.004_bib46","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/jnci\/88.21.1550","article-title":"Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial","volume":"88","author":"Omenn","year":"1996","journal-title":"Journal of the National Cancer Institute"},{"issue":"1","key":"10.1016\/bs.ircmb.2023.05.004_bib47","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: An emerging target in small cell lung cancer","volume":"12","author":"Owen","year":"2019","journal-title":"Journal of Hematology & Oncology"},{"issue":"4","key":"10.1016\/bs.ircmb.2023.05.004_bib48","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/mt.2011.276","article-title":"The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers","volume":"20","author":"Parato","year":"2012","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"7","key":"10.1016\/bs.ircmb.2023.05.004_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100782","article-title":"Blood outgrowth endothelial cells as a cellular carrier for oncolytic vesicular stomatitis virus expressing interferon-beta in preclinical models of non-small cell lung cancer","volume":"13","author":"Patel","year":"2020","journal-title":"Translational Oncology"},{"issue":"11\u201312","key":"10.1016\/bs.ircmb.2023.05.004_bib50","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41417-018-0074-6","article-title":"JAK\/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models","volume":"26","author":"Patel","year":"2019","journal-title":"Cancer Gene Therapy"},{"issue":"3","key":"10.1016\/bs.ircmb.2023.05.004_bib51","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.3390\/curroncol30030239","article-title":"Stage III non-small-cell lung cancer: An overview of treatment options","volume":"30","author":"Petrella","year":"2023","journal-title":"Current Oncology (Toronto, Ont.)"},{"issue":"2","key":"10.1016\/bs.ircmb.2023.05.004_bib52","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/mt.2013.249","article-title":"Maraba virus as a potent oncolytic vaccine vector","volume":"22","author":"Pol","year":"2014","journal-title":"Molecular Therapy: the Journal of the American Society of Gene Therapy"},{"issue":"12","key":"10.1016\/bs.ircmb.2023.05.004_bib53","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1470-2045(11)70259-5","article-title":"Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: A controlled phase 2B trial","volume":"12","author":"Quoix","year":"2011","journal-title":"The Lancet Oncology"},{"issue":"7","key":"10.1016\/bs.ircmb.2023.05.004_bib54","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/JTO.0b013e31817c6b4f","article-title":"A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III\/IV Non-small cell lung cancer","volume":"3","author":"Ramlau","year":"2008","journal-title":"Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer"},{"issue":"4","key":"10.1016\/bs.ircmb.2023.05.004_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040820","article-title":"Pathology and Classification of SCLC","volume":"13","author":"Raso","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/bs.ircmb.2023.05.004_bib56","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1056\/NEJMra1703413","article-title":"Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer","volume":"377","author":"Reck","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"21","key":"10.1016\/bs.ircmb.2023.05.004_bib57","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/jnci\/djm198","article-title":"Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers","volume":"99","author":"Reddy","year":"2007","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/bs.ircmb.2023.05.004_bib58","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"issue":"7","key":"10.1016\/bs.ircmb.2023.05.004_bib59","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","article-title":"Remission of disseminated cancer after systemic oncolytic virotherapy","volume":"89","author":"Russell","year":"2014","journal-title":"Mayo Clinic Proceedings"},{"issue":"6","key":"10.1016\/bs.ircmb.2023.05.004_bib60","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/15384047.2017.1323580","article-title":"Current status of research and treatment for non-small cell lung cancer in never-smoking females","volume":"18","author":"Saito","year":"2017","journal-title":"Cancer Biology & Therapy"},{"issue":"1","key":"10.1016\/bs.ircmb.2023.05.004_bib61","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1038\/s41598-023-33126-x","article-title":"Coxsackievirus A11 is an immunostimulatory oncolytic virus that induces complete tumor regression in a human non-small cell lung cancer","volume":"13","author":"Sakamoto","year":"2023","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.ircmb.2023.05.004_bib62","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jconrel.2016.01.001","article-title":"Adeno-associated virus (AAV) vectors in cancer gene therapy","volume":"240","author":"Santiago-Ortiz","year":"2016","journal-title":"Journal of Controlled Release: Official Journal of the Controlled Release Society"},{"issue":"5","key":"10.1016\/bs.ircmb.2023.05.004_bib63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5501\/wjv.v10.i5.229","article-title":"Oncolytic virus therapy in cancer: A current review","volume":"10","author":"Santos Apolonio","year":"2021","journal-title":"World Journal of Virology"},{"issue":"8","key":"10.1016\/bs.ircmb.2023.05.004_bib64","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41416-019-0574-7","article-title":"The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer","volume":"121","author":"Schreiber","year":"2019","journal-title":"British Journal of Cancer"},{"issue":"6","key":"10.1016\/bs.ircmb.2023.05.004_bib65","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1200\/JCO.2001.19.6.1750","article-title":"Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study","volume":"19","author":"Schuler","year":"2001","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"9","key":"10.1016\/bs.ircmb.2023.05.004_bib66","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1158\/0008-5472.CAN-05-4352","article-title":"Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control","volume":"66","author":"Simpson","year":"2006","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.05.004_bib67","article-title":"Dendritic cell-based immunotherapy in lung cancer","volume":"11","author":"Stevens","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/bs.ircmb.2023.05.004_bib68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1158\/0008-5472.CAN-12-1993","article-title":"Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells","volume":"73","author":"Tai","year":"2013","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/bs.ircmb.2023.05.004_bib69","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s40425-019-0682-1","article-title":"Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1","volume":"7","author":"Thomas","year":"2019","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"issue":"1","key":"10.1016\/bs.ircmb.2023.05.004_bib70","first-page":"153","article-title":"In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity","volume":"61","author":"Todo","year":"2001","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/bs.ircmb.2023.05.004_bib71","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3892\/mco.2017.1277","article-title":"Asbestos-related lung cancers: A retrospective clinical and pathological study","volume":"7","author":"Uguen","year":"2017","journal-title":"Molecular and Clinical Oncology"},{"issue":"9","key":"10.1016\/bs.ircmb.2023.05.004_bib72","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1158\/1078-0432.CCR-05-1187","article-title":"Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung","volume":"12","author":"Varghese","year":"2006","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"6","key":"10.1016\/bs.ircmb.2023.05.004_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002373","article-title":"Oncolytic parainfluenza virus combines with NK cells to mediate killing of infected and non-infected lung cancer cells within 3D spheroids: Role of type I and type III interferon signaling","volume":"9","author":"Varudkar","year":"2021","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"issue":"6","key":"10.1016\/bs.ircmb.2023.05.004_bib74","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/cncr.29856","article-title":"Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors","volume":"122","author":"Villalona-Calero","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2023.05.004_bib75","first-page":"103","article-title":"The implications of IL-15 trans-presentation on the immune response","volume":"156","author":"Waldmann","year":"2022","journal-title":"Advances in Immunology"},{"issue":"3","key":"10.1016\/bs.ircmb.2023.05.004_bib76","first-page":"757","article-title":"Oncolytic herpes simplex virus treatment of metastatic breast cancer","volume":"40","author":"Wang","year":"2012","journal-title":"International Journal of Oncology"},{"issue":"1","key":"10.1016\/bs.ircmb.2023.05.004_bib77","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","article-title":"SCLC: Epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection","volume":"18","author":"Wang","year":"2023","journal-title":"Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer"},{"issue":"3","key":"10.1016\/bs.ircmb.2023.05.004_bib78","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41590-023-01428-x","article-title":"Influenza-trained mucosal-resident alveolar macrophages confer long-term antitumor immunity in the lungs","volume":"24","author":"Wang","year":"2023","journal-title":"Nature Immunology"},{"issue":"6","key":"10.1016\/bs.ircmb.2023.05.004_bib79","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Current Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.004_bib80","first-page":"191","article-title":"Advances in therapeutic cancer vaccines","volume":"130","author":"Wong","year":"2016","journal-title":"Advances in Immunology"},{"issue":"12","key":"10.1016\/bs.ircmb.2023.05.004_bib81","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/cgt.2008.31","article-title":"Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors","volume":"15","author":"Yaacov","year":"2008","journal-title":"Cancer Gene Therapy"},{"issue":"1","key":"10.1016\/bs.ircmb.2023.05.004_bib82","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3892\/mmr.2014.2657","article-title":"Apoptotic induction of lung adenocarcinoma A549 cells infected by recombinant RVG Newcastle disease virus (rL-RVG) in vitro","volume":"11","author":"Yan","year":"2015","journal-title":"Molecular Medicine Report"},{"key":"10.1016\/bs.ircmb.2023.05.004_bib83","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/DDDT.S43184","article-title":"Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: A phase II, randomized study","volume":"7","author":"Zarogoulidis","year":"2013","journal-title":"Drug Design, Development and Therapy"},{"issue":"2","key":"10.1016\/bs.ircmb.2023.05.004_bib84","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0169-5002(95)00583-8","article-title":"Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: A randomized trial","volume":"15","author":"Zarogoulidis","year":"1996","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"1","key":"10.1016\/bs.ircmb.2023.05.004_bib85","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bbrc.2015.07.130","article-title":"Inactivated Sendai virus induces apoptosis and autophagy via the PI3K\/Akt\/mTOR\/p70S6K pathway in human non-small cell lung cancer cells","volume":"465","author":"Zhang","year":"2015","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"1","key":"10.1016\/bs.ircmb.2023.05.004_bib86","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities","volume":"17","author":"Zhang","year":"2018","journal-title":"Molecular Cancer"}],"container-title":["International Review of Cell and Molecular Biology","Viral Vectors in Cancer Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644823000667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644823000667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T15:33:41Z","timestamp":1753457621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644823000667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780443192494"],"references-count":86,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2023.05.004","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}